Immuno Oncology | Topics

Ongoing Phase 1/2 Trial of FLX475 Shows Promising Activity in Multiple Cancer Indications
November 17, 2020

The results demonstrated preliminary evidence of monotherapy activity, encouraging efficacy in combination with the PD-1 checkpoint inhibitor pembrolizumab (Keytruda), and biomarker data supporting FLX475’s mechanism of action.

Higher Serum PD-L1 Level Predicts Increased OS With Lapatinib vs Trastuzumab in CCTG MA.31 Study
October 18, 2020

The researchers hypothesized “that serum PD-L1 may identify a subgroup of patients with HER2-positive [metastatic breast cancer] who may benefit the most from the addition of novel immunotherapies to trastuzumab.”

6-Month PFS for 12-Month OS Model Appears Effective for Estimating 12-Month OS
October 07, 2020

Researchers suggested these findings may assist in better selection and prioritization of immune checkpoint inhibitor agents for testing in randomized clinical trials based on phase 2 single arm randomized clinical trial results.